Recommendations from the Industry Liaison Group to the Executive Committee of the Pharmacogenetics Research Network

Stanford University

Start Date: 3/11/2002 7:00 AM

End Date: 3/11/2002 3:00 PM

Executive Summary

The Industry Liaison Group met with members of the Pharmacogenetics Research Network on the evening of March 11, 2002 at Stanford University. At their meeting, the group considered the newest release of PharmGKB (available at, and discussed the “levels of evidence” model for relating phenotype to genotype information as four categories: molecular and cellular assays, pharmacokinetics, pharmacodynamics, and clinical outcomes.

There was also a discussion of the current terminology used to categorize samples derived from clinical pharmacogenetic studies, including areas where standards are not yet set. Additionally, the joint group considered the issues underlying communication of the importance of pharmacogenetics to the public and the press, and the distinction between research studies and current medical practice. They agreed that this is a challenging area, where the network's goal is to educate and yet not endorse.

The meeting included informal exchanges around the topic of scientific opportunities in the field for academia and for industry. The evening concluded with the attendees looking forward to attending the public meeting the next day, March 12th, in Fairchild Auditorium at Stanford University. A summary of the presentations at that day's meeting can be found at


Donald C. Anderson, M.D.
Pharmacia Corporation
7000 Portage Road
Kalamazoo, Michigan 49001-0199

Wayne H. Anderson, Ph.D.*
Building 5, Room 5808
P.O. Box 13398
Research Triangle Park, North Carolina 27709

Lee E. Babiss, Ph.D. **
Hoffmann-La Roche Inc.
Preclinical Research and Development
340 Kingsland Street
Nutley, New Jersey 07110

Andrew Joseph Dorner, Ph.D.*,**
Wyeth Research
2 Burtt Road
Andover, Massachusetts 01810

Daniel Farkas, Ph.D.*, **
Motorola Life Sciences
757 South Raymond Avenue
Pasadena, California 91105

Larry Gelbert, Ph.D.*, **
Research Scientist Research Technologies and Proteins
Eli Lilly and Company
DC 0444
Lilly Corporate Center
Indianapolis, Indiana 46285

Penelope K. Manasco, M.D**
First Genetic Trust
Three Parkway North Center
Deerfield, IL 60015

Glenn A. Miller, Ph.D.*
Genzyme Corporation
1 Mountain Road
Framingham, Massachusetts 01701

Brian B. Spear, Ph.D.
Abbott Laboratories
Department 424, AP6A-1
100 Abbott Park Road
Abbott Park, Illinois 60064-6008

Vincent P. Stanton, Jr., M.D.
Variagenics, Inc.
60 Hampshire Street
Cambridge, Massachusetts 02139

NIGMS Program Director

Rochelle M. Long, Ph.D.
National Institute of General Medical Sciences
National Institutes of Health
Natcher Building, Room 2AS.49G
45 Center Drive MSC 6200
Bethesda, Maryland 20892-6200
Tel: (301) 594-3827
Fax: (301) 480-2802


Gillian R. Woollett, M.A., D.Phil.
Pharmaceutical Research and Manufacturers of America
110 Fifteenth Street, NW
Washington, D.C. 20005

* New members in 2002

** Not in attendance


6:00 p.m. — Dinner

7:00 p.m. — Welcome on behalf of NIH
Rochelle Long

7:15 p.m. — Review of Recommendations from January 11, 2001 Meeting
Rochelle Long and Mark Ratain

7:30 p.m. — PharmGKB: Status and Opportunities
Russ Altman

8:00 p.m. — Potential Areas of Collaboration: Human Subjects Issues and Nomenclature
Brian Spear and Scott Weiss

8:30 p.m. — Communications with the Public: Collaborations Between Industry and Network
Kathy Giacomini and Alison Davis

9:00 p.m. — Other Potential Areas of Collaboration (General Discussion)
Howard McLeod and Vince Stanton

9:30 p.m. — Adjourn